REarranged during Transfection (RET) gene fusion is one of the common oncogenic variants in non-small cell lung cancers (NSCLCs). However, few RET fusion-positive cases have partner intergenic-breakpoint fusions, in which the partner breakpoint localizes to intergenic regions.

Amoy Diagnostics and Amgen on Thursday said that they have entered a strategic partnership to develop a companion diagnostic for the Japanese market to identify non-small cell lung cancer patients for Amgen's KRAS G12C inhibitor, sotorasib (Lumakras).

On August 5, 2021, Pillar Biosciences announced the FDA has given PMA to its oncoReveal™ Dx Lung and Colon Cancer Assay, an NGS tissue-based companion diagnostic test for the detection of somatic mutations in DNA derived from non-small cell lung cancer (NSCLC) and colorectal (CRC) cancer tumors

Agilent Technologies on Tuesday announced that it has received CE marking for the expanded use of its PD-L1 IHC 22C3 pharmDx companion diagnostic assay in patients with non-small cell lung cancer.

Biodesix isn’t looking to just be another company with lung cancer detection tests. It wants to be the lung cancer detection company. And with its most recent acquisition, the Boulder, CO-just might achieve that goal.